Quick Answer
CITIUS ONCOLOGY, INC. reported Operating Income Loss of -$23.52 million for the year ending 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -14.3% in Operating Income Loss from 2024 to 2025.
- This data is from CITIUS ONCOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$147.9 thousand | Q2 2023: -$199.6 thousand | Q3 2023: -$421.5 thousand | Q1 2024: -$268.4 thousand | Q2 2024: -$4.63 million | Q4 2024: -$6.39 million | Q2 2025: -$4.94 million | Q4 2025: -$5.25 million.
- Over the full 4 years of available data (2022 to 2025), CITIUS ONCOLOGY, INC.'s Operating Income Loss has declined by 16,931.3%.
- Historical annual values: Fiscal year 2025: -$23.52 million | Fiscal year 2024: -$20.57 million | Fiscal year 2023: -$1.01 million | Fiscal year 2022: -$138.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: